High-frequency repetitive transcranial magnetic stimulation accelerates and enhances the clinical response to antidepressants in major depression: a meta-analysis of …

MT Berlim, F Van den Eynde… - The Journal of clinical …, 2013 - psychiatrist.com
Objective: High-frequency repetitive transcranial magnetic stimulation (HF-rTMS) is a safe
and effective treatment for major depression. However, its utility as a strategy to accelerate …

[HTML][HTML] Mitochondrial and Cellular Function in Fibroblasts, Induced Neurons, and Astrocytes Derived from Case Study Patients: Insights into Major Depression as a …

I Cardon, S Grobecker, S Kücükoktay, S Bader… - International Journal of …, 2024 - mdpi.com
The link between mitochondria and major depressive disorder (MDD) is increasingly
evident, underscored both by mitochondria's involvement in many mechanisms identified in …

Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview

MT Berlim, MP Fleck, G Turecki - Annals of medicine, 2008 - Taylor & Francis
A significant proportion of depressed patients eventually present with treatment‐
resistant/refractory major depression (TRD), a debilitating condition that imposes significant …

Antidepressant-like effects of an alkaloid extract of the aerial parts of Annona cherimolia in mice

M Martínez-Vázquez, R Estrada-Reyes… - Journal of …, 2012 - Elsevier
ETHNOPHARMACOLOGICAL RELEVANCE: Several species of Annona (Annonaceae) are
used in traditional Mexican medicine by their anti-anxiety, anticonvulsant and tranquilizing …

Augmentation strategies for treatment‐resistant depression: a literature review

AF Carvalho, JL Cavalcante… - Journal of clinical …, 2007 - Wiley Online Library
Background: The large majority of depressed patients fail to remit on the first antidepressant
prescribed. These patients with residual symptoms have higher relapse rates and poorer …

Combination therapy for depression

M Fava - US Patent App. 12/140,498, 2009 - Google Patents
It has been discovered that administering a combi nation of agents, bupropion and (at least
one) serotonin 5-HT, partial agonist, such as azapirones, preferably bus pirone, provides …

Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study

D Khajavi, M Farokhnia, A Modabbernia… - The Journal of clinical …, 2012 - psychiatrist.com
Method: In this randomized double-blind placebo-controlled study, patients were assessed
in the outpatient clinics of 2 large hospitals from November 2011 to January 2012. Forty …

[HTML][HTML] Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders

J Wolff, P Reißner, G Hefner, C Normann, K Kaier… - PLoS …, 2021 - journals.plos.org
Introduction The aim of this study was to describe the number and type of drugs used to treat
depressive disorders in inpatient psychiatry and to analyse the determinants of potential …

Therapeutic options in treatment-resistant depression

E Vieta, F Colom - Annals of medicine, 2011 - Taylor & Francis
The phenomenon of treatment-resistant depression (TRD), described as the occurrence of
an inadequate response after an adequate treatment with antidepressant agents (in terms of …

Limitations in efficacy of antidepressant monotherapy

AJ Rush - Journal of Clinical Psychiatry, 2007 - psychiatrist.com
Treatment for major depressive disorder does not achieve remission in about 50% of
patients following 2 treatment trials. Researchers conducted the Sequenced Treatment …